Daniel Schneiderman

Daniel Schneiderman

Director of Finance/CFO at PASITHEA THERAPEUTICS CORP.

Net worth: 19 067 $ as of 2026-05-30

48 year
Health Technology
Finance
Consumer Services

Profile

Daniel H.
Schneiderman
is Chief Financial Officer at Pasithea Therapeutics Corp.
since 2022.
Formerly, Chief Financial Officer at GridAI Technologies Corp.
from 2020 to 2022.
Secretary, Vice President-Finance & Controller at MetaStat, Inc. from 2012 to 2018.
Chief Financial Officer at Biophytis SA from 2018 to 2019.
Vice President-Investment Banking at Burnham Hill Partners LLC from 2004 to 2012.
Director at Unleashed Ny from 1996 to 2000.
Chief Financial Officer at Biophytis, Inc. Education includes undergraduate studies at Tulane University (Louisiana).

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-04-30 26,667 ( 0.08% ) 19 067 $ 2026-05-30

Daniel Schneiderman active positions

CompaniesPositionStart
PASITHEA THERAPEUTICS CORP. Director of Finance/CFO 2022-10-10

Former positions of Daniel Schneiderman

CompaniesPositionEnd
GRIDAI TECHNOLOGIES CORP. Director of Finance/CFO 2022-02-27
BIOPHYTIS S.A. Director of Finance/CFO 2019-11-30
METASTAT, INC. Comptroller/Controller/Auditor 2018-07-31
Corporate Officer/Principal 2011-12-31
Unleashed Ny
Director/Board Member 1999-12-31
See the detail of Daniel Schneiderman's experience

Training of Daniel Schneiderman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

18

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies8

Finance

Consumer Services

Health Technology

Producer Manufacturing

Health Technology

Unleashed Ny

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Daniel Schneiderman